That gap is the entire business model. But margin on paper ≠ margin in the bank — third-party testing, lyophilization quality, payment processing and chargebacks all take their cut. Slide the numbers yourself:

Big pharma's GLP-1 blockbusters are worth tens of billions — and the players holding them do not want unregulated resellers riding their demand curve while exclusivity battles play out. So the pressure moves down the chain: FDA warning letters, compounding-pharmacy crackdowns, payment processors dropping peptide merchants, ad platforms banning the keywords.

Every gold rush ends the same way — the money is made before the sheriff arrives. The people who built stores, supplier relationships and buyer lists before the squeeze are the ones who get acquired, pivot, or cash out. The ones who arrive after get seized domains.

The moment a vial is marketed for human use, you're not a reseller anymore — you're an unlicensed drug distributor. The operators who survive treat compliance as product: research-only labeling, no dosage claims, no before/after photos, no human-use language anywhere — site, ads, emails, DMs.

Your real product isn't the peptide. It's the paperwork: batch-specific COAs, third-party HPLC/mass-spec results, and a paper trail from factory to shelf. In a grey market, proof is the brand.

Scammers exploit exactly one thing: an unregulated grey market full of buyers holding no information. Polished websites, "wholesale reps" on fresh SIM cards, stolen lab reports. Meanwhile the real factories barely know what a Google results page is — no SEO, no English keywords, no ads. You will not keyword-search your way to a synthesis plant.

Who you actually meet out there falls into five species: SIM-farm scammers posing as factories · middlemen reselling verified factories' output under the factory's identity · middlemen who will ship you sugar powder if you chase margin hard enough · real factories (some dropped MOQ to 3 kits) · and trading houses wired into science centers. Telling them apart in one conversation is a learnable skill.

Open Janoshik's public database and you'll find pages of results booked under throwaway customer names — JD, JP, MJ, OK, AAA. Your "factory" points at one and shrugs: that's me, I just keep a low profile. There is no way to prove it isn't. And even a 100% genuine report answers only one question: what was inside the one vial that got mailed to the lab — not the batch about to land at your door.

Add the rest of the COA deception playbook — photoshopped PDFs, cloned QR codes, one good batch's report reused for a year, expired lot numbers — and the rule writes itself: trust only the test you or your community commissioned, tied to the lot in your hand.

Peptide resale is not a "build a store and they will come" game — ad platforms ban the niche on sight, so distribution is earned through communities, email lists, SEO and word of mouth. Operators with any selling scar tissue ramp in weeks; total beginners should budget months to learn the channel game.

The same pharma giants squeezing the grey market also hold the line at the biggest merchant services: Stripe, PayPal and Square ban peptide sellers on sight, terminate without appeal, and can park your money for 90–180 days. Worse — a termination can land you on the industry MATCH list, a shared blacklist that makes mainstream providers decline you on application, sometimes for years.

So veterans keep a deliberate distance from the popular processors and run high-risk merchant accounts, eCheck/ACH and self-hosted crypto instead. In the playbook PDF we shortlisted vetted high-risk merchant providers that actually board this niche — pick yours there instead of learning the MATCH list firsthand.